Skip to main content
. 2020 Aug 27;18:323. doi: 10.1186/s12967-020-02493-8

Table 2.

Association of clinicopathologic variables with low-molecular weight (LMW) cfDNA concentration after bead purification and size-selection

LMW cfDNA (ng/mL) p-value
 Full cohort (N = 113) 23.8 (14.9, 44.4)
  Benign (N = 22) 15.5 (9.3, 25.8) 0.006
  Cancer (N = 91) 25.8 (16.0, 49.6)
 Histologic subtype 0.006
  G1 EAC (N = 16) 35.3 (14.1, 83.5)
  G2 EAC (N = 15) 23.4 (17.6, 28.0)
  G3 EAC (N = 16) 23.9 (17.8, 41.9)
  UPSC (N = 15) 21.3 (14.3, 32.9)
  CS (N = 15) 32.2 (17.9, 79.0)
  LMS (N = 8) 65.4 (45.7, 164.3)
  CCC (N = 6) 13.8 (8.0, 26.0)
 Grade 0.04
  Grade 1 (N = 16) 35.3 (14.1, 83.5)
  Grade 2 (N = 15) 23.4 (17.6, 28.0)
  Grade 3 (N = 60) 24.9 (16.1, 51.3)
 Stage of cancer 0.03
  Stage I (N = 42) 24.0 (14.7, 47.1)
  Stage II (N = 16) 24.3 (16.8, 37.8)
  Stage III (N = 22) 26.6 (18.8, 36.6)
  Stage IV (N = 11) 57.2 (16.4, 246.1)
 Lymphovascular space invasion 0.04
  Absent 21.6 (12.8, 39.3)
  Present 30.4 (17.8, 54.6)
 % Myometrial invasion 0.32
 Tumor size 0.006
 Lymph node status
  Negative 23.4 (14.4, 44.5) 0.39
  Positive 30.4 (17.0, 44.4)
 Age 0.38
 Body mass index 0.53
 Race
  White 23.8 (14.9, 36.2) 0.66
  Non-White 24.3 (14.8, 46.6)